Diagnostic testing solutions provider Quidel has received a CE Mark for its diagnostic assay TriageTrue High Sensitivity Troponin I Test for determining troponin I in EDTA anticoagulated whole blood and plasma specimens.

The single-use fluorescence immunoassay device will be used as an aid to diagnose myocardial infarction (MI), or heart attack, for use with the company’s Triage MeterPro instrumented system.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“According to Quidel, the new troponin assays are capable of detecting and quantitating troponin at lower levels.”

This will be helpful to determine the concentration of troponin I in whole blood or plasma specimens, anticoagulated with EDTA.

MI occurs when a part of the heart muscle fails to receive enough blood flow.

Quidel president and CEO Douglas Bryant said: “We are proud to introduce the world’s first Near Patient high sensitivity diagnostic test for Troponin I, and are excited by the positive impact that we can make in accurately providing results in 20 minutes or less to aid in diagnosing a heart attack.”

According to Quidel, the new troponin assays are capable of detecting and quantitating troponin at lower levels.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TriageTrue features a redesigned cartridge that is said to improve sensitivity and precision of the assay.

The MeterPro screen displays the results in less than 20 minutes from the addition of specimen to the device.

All results are stored in the MeterPro memory to display or print based on requirement.

The device enables performing of hsTnI testing in the emergency department, urgent care facilities and other decentralised settings.

Quidel’s products are marketed under the Sofia, QuickVue, D3 Direct Detection, Thyretain, Triage and InflammaDry brand names.